AU8022900B2

AU8022900B2 -

Info

Publication number: AU8022900B2
Authority: AU; Australia
Prior art keywords: metformin; low dose; glyburide; antidiabetic agent; insulin
Prior art date: 2005-06-16
Legal status : Active

Application number

Other languages

English (en)

Publication date

2005-06-16

Links

XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 251
229960003105 Metformin Drugs 0.000 claims description 245
239000000203 mixture Substances 0.000 claims description 185
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 86
206010012601 Diabetes mellitus Diseases 0.000 claims description 68
239000003814 drug Substances 0.000 claims description 68
239000003472 antidiabetic agent Substances 0.000 claims description 60
229940079593 drugs Drugs 0.000 claims description 59
WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 56
239000008103 glucose Substances 0.000 claims description 56
238000009093 first-line therapy Methods 0.000 claims description 55
239000008194 pharmaceutical composition Substances 0.000 claims description 47
102000004877 Insulin Human genes 0.000 claims description 43
108090001061 Insulin Proteins 0.000 claims description 43
208000001072 Type 2 Diabetes Mellitus Diseases 0.000 claims description 35
230000000291 postprandial Effects 0.000 claims description 35
230000002401 inhibitory effect Effects 0.000 claims description 31
239000003112 inhibitor Substances 0.000 claims description 30
102100003818 GCG Human genes 0.000 claims description 29
DTHNMHAUYICORS-KTKZVXAJSA-N 107444-51-9 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 28
101710042131 GCG Proteins 0.000 claims description 28
238000009472 formulation Methods 0.000 claims description 23
231100000486 side effect Toxicity 0.000 claims description 23
230000002829 reduced Effects 0.000 claims description 22
ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims description 16
102000004366 Glucosidases Human genes 0.000 claims description 16
108010056771 Glucosidases Proteins 0.000 claims description 16
102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims description 16
108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims description 16
239000000556 agonist Substances 0.000 claims description 16
230000003247 decreasing Effects 0.000 claims description 16
SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 claims description 14
229950004994 Meglitinide Drugs 0.000 claims description 14
239000002552 dosage form Substances 0.000 claims description 11
206010022489 Insulin resistance Diseases 0.000 claims description 9
108010054147 Hemoglobins Proteins 0.000 claims description 8
102000001554 Hemoglobins Human genes 0.000 claims description 8
230000001965 increased Effects 0.000 claims description 8
XUFXOAAUWZOOIT-WVJZLWNXSA-N (2S,3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-WVJZLWNXSA-N 0.000 claims description 5
210000004369 Blood Anatomy 0.000 claims description 5
229960002632 acarbose Drugs 0.000 claims description 5
239000008280 blood Substances 0.000 claims description 5
FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 claims description 4
230000003178 anti-diabetic Effects 0.000 claims description 4
230000003345 hyperglycaemic Effects 0.000 claims description 4
229960002354 repaglinide Drugs 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 2
ZNNLBTZKUZBEKO-UHFFFAOYSA-N Glibenclamide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 159
229960004580 GLIBENCLAMIDE Drugs 0.000 description 158
229940014653 Glyburide Drugs 0.000 description 143
230000002641 glycemic Effects 0.000 description 72
WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 52
239000003826 tablet Substances 0.000 description 51
238000009097 single-agent therapy Methods 0.000 description 45
238000002560 therapeutic procedure Methods 0.000 description 41
229940068196 placebo Drugs 0.000 description 37
239000000902 placebo Substances 0.000 description 37
239000012071 phase Substances 0.000 description 30
238000002648 combination therapy Methods 0.000 description 28
YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical compound OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 21
239000002245 particle Substances 0.000 description 20
230000004044 response Effects 0.000 description 17
235000005911 diet Nutrition 0.000 description 16
239000003795 chemical substances by application Substances 0.000 description 15
235000020828 fasting Nutrition 0.000 description 15
230000001225 therapeutic Effects 0.000 description 15
210000002381 Plasma Anatomy 0.000 description 14
230000002058 anti-hyperglycaemic Effects 0.000 description 14
230000037213 diet Effects 0.000 description 14
230000002218 hypoglycaemic Effects 0.000 description 14
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
206010020993 Hypoglycaemia Diseases 0.000 description 13
-1 for example Chemical compound 0.000 description 12
230000002496 gastric Effects 0.000 description 10
239000006186 oral dosage form Substances 0.000 description 10
230000001603 reducing Effects 0.000 description 9
238000006722 reduction reaction Methods 0.000 description 9
231100000730 tolerability Toxicity 0.000 description 9
229940095884 Glucophage Drugs 0.000 description 8
231100000494 adverse effect Toxicity 0.000 description 8
239000002775 capsule Substances 0.000 description 8
235000012054 meals Nutrition 0.000 description 8
229920000036 polyvinylpyrrolidone Polymers 0.000 description 8
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 8
235000019359 magnesium stearate Nutrition 0.000 description 7
238000000034 method Methods 0.000 description 7
230000004797 therapeutic response Effects 0.000 description 7
229920000168 Microcrystalline cellulose Polymers 0.000 description 6
OETHQSJEHLVLGH-UHFFFAOYSA-N [amino-(diaminomethylideneamino)methylidene]-dimethylazanium;chloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 6
239000011230 binding agent Substances 0.000 description 6
230000000694 effects Effects 0.000 description 6
239000008187 granular material Substances 0.000 description 6
201000001421 hyperglycemia Diseases 0.000 description 6
239000004615 ingredient Substances 0.000 description 6
230000002503 metabolic Effects 0.000 description 6
235000019813 microcrystalline cellulose Nutrition 0.000 description 6
239000008108 microcrystalline cellulose Substances 0.000 description 6
229940016286 microcrystalline cellulose Drugs 0.000 description 6
239000001267 polyvinylpyrrolidone Substances 0.000 description 6
150000003839 salts Chemical class 0.000 description 6
238000009094 second-line therapy Methods 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
238000004448 titration Methods 0.000 description 6
230000004584 weight gain Effects 0.000 description 6
235000019786 weight gain Nutrition 0.000 description 6
VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 5
210000000496 Pancreas Anatomy 0.000 description 5
GXPHKUHSUJUWKP-UHFFFAOYSA-N Troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 5
201000010099 disease Diseases 0.000 description 5
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 5
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 5
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 5
150000002632 lipids Chemical class 0.000 description 5
231100000489 sensitizer Toxicity 0.000 description 5
229960001641 troglitazone Drugs 0.000 description 5
229960001681 Croscarmellose Sodium Drugs 0.000 description 4
229920002785 Croscarmellose sodium Polymers 0.000 description 4
229960004329 Metformin hydrochloride Drugs 0.000 description 4
HYAFETHFCAUJAY-UHFFFAOYSA-N Pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 4
229960005095 Pioglitazone Drugs 0.000 description 4
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 4
229940090121 Sulfonylureas for blood glucose lowering Drugs 0.000 description 4
235000010980 cellulose Nutrition 0.000 description 4
229920002678 cellulose Polymers 0.000 description 4
239000001913 cellulose Substances 0.000 description 4
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 4
239000003085 diluting agent Substances 0.000 description 4
230000002349 favourable Effects 0.000 description 4
238000011068 load Methods 0.000 description 4
239000003550 marker Substances 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
229960004586 rosiglitazone Drugs 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
230000036912 Bioavailability Effects 0.000 description 3
IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
230000035514 bioavailability Effects 0.000 description 3
238000003745 diagnosis Methods 0.000 description 3
238000009826 distribution Methods 0.000 description 3
239000000945 filler Substances 0.000 description 3
239000000314 lubricant Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
229960001110 miglitol Drugs 0.000 description 3
239000003538 oral antidiabetic agent Substances 0.000 description 3
230000001991 pathophysiological Effects 0.000 description 3
230000035945 sensitivity Effects 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
230000002195 synergetic Effects 0.000 description 3
LJTHZLWYIHCHKN-UHFFFAOYSA-N 1-carbamimidoyl-1-(2-phenylethyl)guanidine;5-chloro-N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide Chemical compound NC(=N)N(C(N)=N)CCC1=CC=CC=C1.COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 LJTHZLWYIHCHKN-UHFFFAOYSA-N 0.000 description 2
RKWGIWYCVPQPMF-UHFFFAOYSA-N 4-chloro-N-[(propylamino)carbonyl]benzenesulfonamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 2
229960001761 Chlorpropamide Drugs 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 2
206010012735 Diarrhoea Diseases 0.000 description 2
206010061818 Disease progression Diseases 0.000 description 2
IXZISFNWUWKBOM-ARQDHWQXSA-N Fructosamine Chemical compound NC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O IXZISFNWUWKBOM-ARQDHWQXSA-N 0.000 description 2
229960000346 Gliclazide Drugs 0.000 description 2
BOVGTQGAOIONJV-UHFFFAOYSA-N Gliclazide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CC2CCCC2C1 BOVGTQGAOIONJV-UHFFFAOYSA-N 0.000 description 2
WIGIZIANZCJQQY-RUCARUNLSA-N Glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 2
229960001381 Glipizide Drugs 0.000 description 2
ZJJXGWJIGJFDTL-UHFFFAOYSA-N Glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 2
229940084094 Glyburide 2.5 MG Drugs 0.000 description 2
108010023302 HDL Cholesterol Proteins 0.000 description 2
210000004153 Islets of Langerhans Anatomy 0.000 description 2
108010028554 LDL Cholesterol Proteins 0.000 description 2
GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
229920000881 Modified starch Polymers 0.000 description 2
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N Palmitic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
229940069328 Povidone Drugs 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
239000008186 active pharmaceutical agent Substances 0.000 description 2
238000007792 addition Methods 0.000 description 2
239000000654 additive Substances 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
239000004203 carnauba wax Substances 0.000 description 2
235000013869 carnauba wax Nutrition 0.000 description 2
230000003915 cell function Effects 0.000 description 2
239000008199 coating composition Substances 0.000 description 2
239000011247 coating layer Substances 0.000 description 2
230000000295 complement Effects 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
230000000875 corresponding Effects 0.000 description 2
230000001186 cumulative Effects 0.000 description 2
201000008286 diarrhea Diseases 0.000 description 2
230000000378 dietary Effects 0.000 description 2
XNCOSPRUTUOJCJ-UHFFFAOYSA-N diguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 2
239000000890 drug combination Substances 0.000 description 2
235000019441 ethanol Nutrition 0.000 description 2
229960004346 glimepiride Drugs 0.000 description 2
238000005469 granulation Methods 0.000 description 2
230000003179 granulation Effects 0.000 description 2
150000003840 hydrochlorides Chemical class 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000003914 insulin secretion Effects 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
239000008101 lactose Substances 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
238000002156 mixing Methods 0.000 description 2
231100000989 no adverse effect Toxicity 0.000 description 2
230000002093 peripheral Effects 0.000 description 2
239000004014 plasticizer Substances 0.000 description 2
DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
239000012453 solvate Substances 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
239000007916 tablet composition Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
150000003626 triacylglycerols Chemical class 0.000 description 2
239000002023 wood Substances 0.000 description 2
IRAAJHYKQDFNFO-SFHVURJKSA-N (2S)-3-[4-[2-[1,3-benzoxazol-2-yl(methyl)amino]ethoxy]phenyl]-2-(2,2,2-trifluoroethoxy)propanoic acid Chemical compound N=1C2=CC=CC=C2OC=1N(C)CCOC1=CC=C(C[C@H](OCC(F)(F)F)C(O)=O)C=C1 IRAAJHYKQDFNFO-SFHVURJKSA-N 0.000 description 1
DXXHHEGZUCEQCJ-UHFFFAOYSA-N (4-chlorophenyl) ethaneperoxoate Chemical compound CC(=O)OOC1=CC=C(Cl)C=C1 DXXHHEGZUCEQCJ-UHFFFAOYSA-N 0.000 description 1
UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-Trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 1
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
KVOBEHAICHPFEF-UHFFFAOYSA-N 3-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound C1=CC=C(C(=O)NCC=2C=CC(=CC=2)C(F)(F)F)C(OC)=C1CC1SC(=O)NC1=O KVOBEHAICHPFEF-UHFFFAOYSA-N 0.000 description 1
XJBOZKOSICCONT-UHFFFAOYSA-N 4,6,6-trimethylbicyclo[3.1.1]hept-2-ene Chemical compound CC1C=CC2C(C)(C)C1C2 XJBOZKOSICCONT-UHFFFAOYSA-N 0.000 description 1
NFFXEUUOMTXWCX-UHFFFAOYSA-N 5-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound C1=C(C(=O)NCC=2C=CC(=CC=2)C(F)(F)F)C(OC)=CC=C1CC1SC(=O)NC1=O NFFXEUUOMTXWCX-UHFFFAOYSA-N 0.000 description 1
NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 description 1
WSMPABBFCFUXFV-UHFFFAOYSA-N 6-amino-2-[[2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]hexanoic acid;hydrobromide Chemical compound Br.NCCCCC(C(O)=O)NC(=O)C(N)CC1=CN=CN1 WSMPABBFCFUXFV-UHFFFAOYSA-N 0.000 description 1
208000004998 Abdominal Pain Diseases 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
235000006491 Acacia senegal Nutrition 0.000 description 1
BCMCBBGGLRIHSE-UHFFFAOYSA-N Benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
HNWXYYXDKGPQTJ-UHFFFAOYSA-N C(C1=CC=CC=C1)NC(C1=C(C(C(C=C1)=O)=O)C=1N=[C-]SC=1)=O Chemical class C(C1=CC=CC=C1)NC(C1=C(C(C(C=C1)=O)=O)C=1N=[C-]SC=1)=O HNWXYYXDKGPQTJ-UHFFFAOYSA-N 0.000 description 1
229960003563 Calcium Carbonate Drugs 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L Calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
208000008787 Cardiovascular Disease Diseases 0.000 description 1
229920002301 Cellulose acetate Polymers 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
208000004981 Coronary Disease Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
QQKNSPHAFATFNQ-UHFFFAOYSA-N Darglitazone Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCC(=O)C(C=C1)=CC=C1CC1SC(=O)NC1=O QQKNSPHAFATFNQ-UHFFFAOYSA-N 0.000 description 1
229950006689 Darglitazone Drugs 0.000 description 1
208000002249 Diabetes Complications Diseases 0.000 description 1
229960002380 Dibutyl Phthalate Drugs 0.000 description 1
DOIRQSBPFJWKBE-UHFFFAOYSA-N Dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 1
FLKPEMZONWLCSK-UHFFFAOYSA-N Diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 1
229950005627 Embonate Drugs 0.000 description 1
MVDXXGIBARMXSA-UHFFFAOYSA-N Englitazone Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(OC(CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-UHFFFAOYSA-N 0.000 description 1
229950002375 Englitazone Drugs 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
108010090776 Glucagon-like peptide 1(7-37) Proteins 0.000 description 1
102400000324 Glucagon-like peptide 1(7-37) Human genes 0.000 description 1
208000002705 Glucose Intolerance Diseases 0.000 description 1
229940084095 Glyburide 1.25 MG Drugs 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
241000282412 Homo Species 0.000 description 1
MDXYQVPFSHFPHS-CVYXXLPWSA-N IRP peptide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C(C)C)NC(=O)[C@H](CCC(=O)OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)OC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)NC(=O)[C@@H](N)CCCCN)C1=CC=CC=C1 MDXYQVPFSHFPHS-CVYXXLPWSA-N 0.000 description 1
206010056997 Impaired fasting glucose Diseases 0.000 description 1
TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
208000006443 Lactic Acidosis Diseases 0.000 description 1
210000004185 Liver Anatomy 0.000 description 1
210000003205 Muscles Anatomy 0.000 description 1
206010028817 Nausea and vomiting symptom Diseases 0.000 description 1
PKWDZWYVIHVNKS-UHFFFAOYSA-N Netoglitazone Chemical compound FC1=CC=CC=C1COC1=CC=C(C=C(CC2C(NC(=O)S2)=O)C=C2)C2=C1 PKWDZWYVIHVNKS-UHFFFAOYSA-N 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
239000004698 Polyethylene (PE) Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
230000000996 additive Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
230000000181 anti-adherence Effects 0.000 description 1
230000000844 anti-bacterial Effects 0.000 description 1
230000003466 anti-cipated Effects 0.000 description 1
230000000111 anti-oxidant Effects 0.000 description 1
239000003911 antiadherent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
230000003190 augmentative Effects 0.000 description 1
235000004251 balanced diet Nutrition 0.000 description 1
230000027455 binding Effects 0.000 description 1
229940090127 blood glucose lowering Alpha glucosidase inhibitors Drugs 0.000 description 1
229940090129 blood glucose lowering drugs Thiazolidinediones Drugs 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
235000021152 breakfast Nutrition 0.000 description 1
239000004067 bulking agent Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
210000004027 cells Anatomy 0.000 description 1
150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
230000002060 circadian Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
229940000425 combination drugs Drugs 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
201000008739 coronary artery disease Diseases 0.000 description 1
230000002596 correlated Effects 0.000 description 1
238000000586 desensitisation Methods 0.000 description 1
230000001627 detrimental Effects 0.000 description 1
125000004212 difluorophenyl group Chemical group 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000002708 enhancing Effects 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000001610 euglycemic Effects 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
231100000198 gastrointestinal adverse effect Toxicity 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
108010063245 glucagon-like peptide 1 (7-36)amide Proteins 0.000 description 1
230000004190 glucose uptake Effects 0.000 description 1
PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
125000005908 glyceryl ester group Chemical group 0.000 description 1
108010036110 hemoglobin AC Proteins 0.000 description 1
230000002440 hepatic Effects 0.000 description 1
229920001477 hydrophilic polymer Polymers 0.000 description 1
229920001600 hydrophobic polymer Polymers 0.000 description 1
238000010902 jet-milling Methods 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
238000002372 labelling Methods 0.000 description 1
238000002356 laser light scattering Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229940035734 metformin and sulfonylureas Drugs 0.000 description 1
125000005397 methacrylic acid ester group Chemical group 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
239000004200 microcrystalline wax Substances 0.000 description 1
235000019808 microcrystalline wax Nutrition 0.000 description 1
230000001264 neutralization Effects 0.000 description 1
235000020925 non fasting Nutrition 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
239000000546 pharmaceutic aid Substances 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002335 preservative Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000000750 progressive Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
150000003222 pyridines Chemical class 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
238000007873 sieving Methods 0.000 description 1
150000004756 silanes Chemical class 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
229940001607 sodium bisulfite Drugs 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
241000894007 species Species 0.000 description 1
239000012177 spermaceti Substances 0.000 description 1
229940084106 spermaceti Drugs 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
150000001467 thiazolidinediones Chemical class 0.000 description 1
238000009095 third-line therapy Methods 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
239000001069 triethyl citrate Substances 0.000 description 1
235000013769 triethyl citrate Nutrition 0.000 description 1
238000004450 types of analysis Methods 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000001993 wax Substances 0.000 description 1
230000003442 weekly Effects 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1
230000003820 β-cell dysfunction Effects 0.000 description 1